Home
    Disclaimer
    5-MeO-DiBF molecular structure

    5-MeO-DiBF Stats & Data

    5-meo-dipbf
    NPS DataHub
    MW275.39
    FormulaC17H25NO2
    IUPACN-[2-(5-methoxy-1-benzofuran-3-yl)ethyl]-N-propan-2-ylpropan-2-amine
    SMILESCOc1ccc2occ(CCN(C(C)C)C(C)C)c2c1
    InChIKeyNBFMSQBTYHYVKP-UHFFFAOYSA-N
    Phenethylamines; Arylalkylamines; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen
    Chemical Class Phenethylamine
    Psychoactive Class Psychedelic
    Half-Life Unknown (active window suggests a few hours; no formal PK)

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT1A receptor agonist
    5-HT2A receptor agonist (partial)
    5-HT2C receptor agonist

    Receptor Binding

    serotonin agonist

    Effect Profile

    Curated + 4 Reports
    Psychedelic 8.0

    Strong visuals, headspace, auditory effects, and body load

    Visual Intensity×3
    10
    Headspace Depth×3
    8
    Auditory Effects×1
    8
    Body Load / Somatic Effects×1
    8
    Empathogen 2.9

    Strong sensory enhancement with moderate stimulation, low euphoria

    Empathy / Social Openness×3
    0
    Euphoria / Mood Elevation×2
    2
    Stimulation×1
    7
    Sensory Enhancement×1
    9

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Oral
    15-45 minutes
    15-30 minutes
    1-2.5 hours
    1-1.5 hours
    5 hours
    Total: 4-6 hours
    Insufflated
    1-4 minutes
    15-30 minutes
    1-2.5 hours
    1-1.5 hours
    5 hours

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown (active window suggests a few hours; no formal PK)
    Addiction Potential
    Low; no physical dependence patterns reported. Mild psychological desire at social/entactogenic doses has been described anecdotally.

    Tolerance Decay

    Full tolerance 1d Half tolerance 7d Baseline ~14d

    Tolerance guidance is extrapolated from general serotonergic psychedelics and community moderator advice to space trials by ≥1 week; empirical data for 5‑MeO‑DiBF specifically are scarce.

    Cross-Tolerances

    Serotonergic psychedelics (e.g., LSD, psilocin)
    50% ●○○
    Other 5‑MeO analogues (e.g., 5‑MeO‑DiPT)
    50% ●○○

    Experience Report Analysis

    Erowid
    4 Reports
    2015–2018 Date Range
    4 With Age Data
    2 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 4 experience reports (4 Erowid)

    4 Reports
    2 Effects Detected
    2 Positive
    0 Adverse
    0 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 2

    Stimulation 100.0% 70%
    Euphoria 75.0% 70%

    Adverse Effects 0

    Form / Preparation

    Most common forms and preparations reported

    Legal Status

    Controlled internationally under the UN Convention on Psychotropic Substances 1971.
    Country Status Notes
    Germany 5-MeO-DiBF is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
    Switzerland 5-MeO-DiBF is a controlled substance specifically named under Verzeichnis E.
    United Kingdom It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.

    Harm Reduction

    drugs.wiki

    - Identity and purity: This compound first appeared in EU early warning logs in late 2015; availability has been sporadic and mislabeling within the tryptamine/benzofuran scene is documented. Whenever possible, use an accredited drug checking service; single reagents are not reliable to confirm identity. Avoid assuming it is 5‑MeO‑DiPT or 5‑MeO‑DMT based on name alone.

    - Dose variability: Community reports span from threshold activity near 10–20 mg oral to strong effects above 100 mg, suggesting variability in material, salt forms, or individual sensitivity. Treat any new batch as unknown potency and titrate cautiously with a milligram scale and volumetric dosing.

    - GI effects: Diarrhoea, stomach cramping, and post‑come‑up headache are frequently reported, especially at higher oral doses. Plan hydration and electrolytes, avoid heavy meals pre-dose, and don’t stack with other GI‑active agents. Persistent vomiting, bloody stools, or severe abdominal pain warrant medical evaluation.

    - Restlessness/legs: Akathisia‑like ‘restless legs’ and body jitter are reported at moderate to high doses; avoid stimulants on the day and consider calm, low‑stimulation settings to reduce agitation.

    - Insufflation care: The intranasal route has a fast onset and shorter total duration but increases local irritation; limit repeated lines, use isotonic rinses afterward, and allow several days of recovery.

    - Redosing: Redosing during the peak tends to increase somatic load more than desirable effects. If chosen at all, wait until effects largely resolve; avoid serial redoses due to unknown pharmacokinetics.

    - Spacing: Allow at least 7–14 days between trials to reduce tolerance, confusion of dose–response, and cumulative stress.

    - Set/setting and consent: Mild entactogenic and erotic tones are reported by some users; plan boundaries and consent in advance and avoid mixing with alcohol or sedatives that impair judgment.

    - Emergencies: Signs of serotonin toxicity (agitation, clonus/tremor, hyperreflexia, hyperthermia) require urgent care. For severe anxiety or dangerous behaviour, a sober sitter and calm environment help; benzodiazepines can abort acute agitation but carry their own risks and should not be pre‑loaded casually.

    ← Back to 5-MeO-DiBF